Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome

The aim of our trial was to evaluate the prognostic significance of qualitative ctDNA analysis on different stages of EGFR mutated non-small cell lung cancer (NSCLC) treatment.We included 99 patients amendable for the first line treatment with either gefitinib/erlotinib (n = 87), afatinib (n = 10) o...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rysev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, V.V. Egorenkov, N.H. Abduloeva, A.O. Ivantsov, E.S. Kuligina, E.N. Imyanitov, V.M. Moiseyenko
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier 2022-01-01
Reeks:Cancer Treatment and Research Communications
Onderwerpen:
NSCLC
EGFR
Targeted therapy
ctDNA
Prognosis
Online toegang:http://www.sciencedirect.com/science/article/pii/S2468294222000132
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items